Abstract Body

Background

Although antiretroviral therapy (ART) has extended the lifespan of people living with HIV (PLWH), it cannot eliminate genome-integrated HIV reservoirs. Approximately 81% of the reservoir remains transcriptionally active, driving immune activation and rapid viral rebound. Silencing these transcriptionally active reservoirs is crucial. Recent studies highlight that DNA and histone methylation can effectively silence cellular transcription, keeping retroviruses in a “deep-latent” state. Leveraging these insights, we developed BrecOFF, a novel HIV-specific epigenome editor, to achieve durable silencing of transcriptionally active HIV.

Methods

BrecOFF is a 148 kDa HIV-specific epigenome editor that integrates the de novo DNA methylation machinery DNTM3A-3L with the KRAB transcriptional repressor domain KOX1. To improve targeting specificity and reduce size, the ~160 kDa dCas9 component of CRISPRoff was replaced with a ~38 kDa catalytically inactive version of Brec1 (dBrec1), an HIV-specific recombinase targeting a conserved 34-bp region in the HIV long terminal repeat (LTR). We evaluated BrecOFF’s ability to bind the HIV LTR and inhibit transcription both transiently and long-term. Additionally, enhanced versions of BrecOFF with alternative KRAB domains were developed, and virus-like particles (VLPs) were engineered for efficient delivery.

Results

Both dBrec1 and BrecOFF bound to the HIV LTR without inducing proviral cleavage. Transient expression of dBrec1 or BrecOFF repressed episomal HIV transcription, but only BrecOFF inhibited basal proviral transcription for over a month, indicating durable epigenomic silencing. Mutational analyses confirmed that DNA and histone methylation are essential for sustained repression. We further enhanced transcriptional silencing by substituting the KOX1 KRAB domain with ZIM2 or ZIM3. Finally, VLPs were validated as an efficient packaging and delivery system for BrecOFF, opening new opportunities to silence HIV in T cells.

Conclusions

BrecOFF represents a promising HIV-specific epigenome editor with significant therapeutic potential. Combining dBrec1’s HIV-specific targeting with the durable epigenomic silencing of CRISPRoff, BrecOFF offers an innovative next-generation gene therapy strategy for a functional HIV cure. The development of the VLP delivery system further supports its translational feasibility for both research and clinical applications.